Recurrent Impetigo: Repeat Cephalexin Treatment
Yes, you can prescribe a second course of cephalexin for recurrent impetigo, but first investigate why the infection recurred and consider whether treatment failure versus true recurrence is occurring.
Initial Assessment of Recurrence
When impetigo returns after initial treatment, you must distinguish between:
- Treatment failure (persistence within 8-10 days): Suggests inadequate initial therapy, resistant organisms, or non-compliance 1
- True recurrence (after initial cure): May indicate recolonization, inadequate decolonization, or ongoing exposure 2
When to Prescribe Another Course of Cephalexin
Cephalexin remains highly effective for impetigo with cure rates of 90% or higher, and can be safely repeated for true recurrences 3. The IDSA guidelines list cephalexin as a first-line agent for impetigo at 250 mg four times daily (adults) or 25-50 mg/kg/day in 3-4 divided doses (children) 4.
Key considerations before repeating:
- Verify compliance with the initial course: Incomplete courses increase resistance risk and treatment failure 5
- Confirm adequate duration: Initial treatment should have been 10 days 6
- Assess for MRSA: If treatment failed despite compliance, consider that community-acquired MRSA may be present, requiring alternative coverage 4
- Rule out reinfection sources: Check for nasal carriage, close contact transmission, or environmental contamination 2
Treatment Algorithm for Recurrent Impetigo
If Initial Treatment Failed (within 8-10 days):
- Do NOT simply repeat cephalexin 1
- Consider culture and sensitivity testing to identify resistant organisms 4
- Switch to an agent with MRSA coverage (clindamycin, trimethoprim-sulfamethoxazole, or doxycycline in adults) 4
If True Recurrence (after initial cure):
- Cephalexin can be repeated at standard dosing for another 10-day course 4, 3
- Consider adding decolonization measures (intranasal mupirocin for 5 days) 4
- Address hygiene factors and close contact screening 2
Important Caveats
The FDA label warns that prolonged or repeated cephalexin use may result in overgrowth of nonsusceptible organisms 5. Monitor carefully for:
- Superinfection during therapy 5
- Development of antibiotic resistance with repeated courses 5
- Gastrointestinal side effects, particularly antibiotic-associated diarrhea 5
For patients with multiple recurrences (≥3 episodes), investigate for:
- Staphylococcal or streptococcal carriage requiring decolonization 4
- Underlying immunodeficiency 4
- Environmental or household transmission requiring broader intervention 2
Antibiotic Stewardship Considerations
Recent data shows that 44.8% of impetigo cases receive systemic antibiotics as first-line therapy, with cephalexin being the most commonly prescribed (53.5%) 7. However, prescribing antibiotics without proven bacterial infection increases resistance risk 5. For limited lesions on recurrence, consider topical mupirocin or retapamulin instead of repeating systemic therapy 4.
Cephalexin has demonstrated equal or superior efficacy compared to dicloxacillin and erythromycin, with the advantage of twice-daily dosing that may improve compliance 2, 1, 3. This makes it a reasonable choice for repeat treatment when true recurrence occurs after proper initial therapy.